Healthcare resource use and associated costs among patients with Crohn’s disease and ulcerative colitis who initiated ustekinumab treatment through BIOADVANCE® program
Summary
Project ID: P2022-123/ 2024 0970 346 000
Research Question/Objectives
Primary objective:
- To compare yearly HCRU and associated costs between 1 year prior to index date and yearly HCRU and associated costs up to 4 years following the index date among patients in Ontario with CD and UC that have initiated ustekinumab treatment through Janssen BIOADVANCE®.
Secondary objectives:
- To describe patient demographic and clinical characteristics at index date or in 1 year before the index date among the study population described in the primary objective
- To compare yearly HCRU and associated costs between 1 year prior to index date and yearly HCRU and associated costs up to 4 years following the index date among patients in Ontario with CD and UC that have initiated and continued ustekinumab treatment through Janssen BIOADVANCE®
- To assess the association of persistence on ustekinumab at 12 months following the index date with the subsequent yearly HCRU and associated costs, if sample size is sufficient
- To assess the association of previous biologic experience at the index date with the yearly HCRU and associated costs following the index date, if sample size is sufficient
- To evaluate the yearly HCRU and associated costs incurred after the index date and during the treatment period prior to the pre-COVID-19 pandemic period, if sample size is sufficient
Exploratory objectives – if feasible:
- To evaluate yearly HCRU and associated costs after ustekinumab treatment discontinuation in the sub-cohort of patients who discontinued ustekinumab during the study period.
Results: Completed
Results: July 2025